PUB - Publikationen an der Universität Bielefeld

BACKGROUND: Neoadjuvant chemotherapy (NACT) is routinely used for patients with triple-negative breast cancer (TNBC). Upfront breast-conserving therapy (BCT) consisting of breast-conserving surgery (BCS) and adjuvant radiotherapy (RT) has been shown to be associated with improved outcome in patients with early TNBC as compared to mastectomy.; METHODS: We identified 2632 patients with early TNBC from the German Breast Group meta-database. Patients with cT1-2 cN0 and ypN0, available surgery and follow-up data were enrolled. Data of 1074 patients from 8 prospective NACT trials were available. Endpoints of interest were locoregional recurrence as first site of relapse (LRR), disease-free survival (DFS) and overall survival (OS). We performed univariate and multivariate Fine-Gray analysis and Cox regression models.; RESULTS: After a median follow-up of 64 months, there were 94 (8.8%) locoregional events as first site of relapse. Absence of pathologic complete response (pCR) was associated with increased LRR upon uni- and multivariate analysis (hazard ratio [HR]=2.28; p<0.001 and HR=2.22; p=0.001). Type of surgery was not associated with LRR. Patients in the BCS-group had better DFS and OS (DFS: HR=0.47; p<0.001 and OS: HR=0.40; p<0.001). BCS was associated with improved DFS and OS upon multivariate analysis (DFS: HR=0.51; p<0.001; and OS HR=0.43; p<0.001), whereas absence of pCR was associated with worse DFS and OS (DFS: HR=2.43; p<0.001; and OS: HR=3.15; p<0.001).; CONCLUSIONS: In this retrospective analysis of patients with early stage node-negative TNBC treated with NACT, BCS was not associated with an increased risk of LRR but with superior DFS and OS. Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.